Alpha Anomeric Overview

  • Year Founded
  • 2018

Year Founded

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • M&A

Alpha Anomeric General Information

Description

Developer of genetic medicines intended to provide the precision tools to modulate new ribonucleic acid (RNA) targets and neuromuscular diseases. The company's medicines are developed by a proprietary alpha anomeric-bicyclo DNA platform that reaches unprecedented precision in RNA modulation by eliminating common side effects of current oligonucleotide chemistries and by increasing the specificity and effectiveness of treatment, enabling physicians to treat patients with severe neuromuscular diseases.

Contact Information

Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Corporate Office
  • 140 Bis, Rue De Rennes
  • 75006 Paris
  • France
+33 07
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Parent Company
Vertical(s)
Corporate Office
  • 140 Bis, Rue De Rennes
  • 75006 Paris
  • France
+33 07

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Alpha Anomeric Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Merger/Acquisition 29-Apr-2025 Completed Generating Revenue
3. Early Stage VC (Series A) 30-Sep-2020 Completed Generating Revenue
2. Early Stage VC (Series A) 14-Feb-2019 $1.71M $1.71M Completed Generating Revenue
1. University Spin-Out 01-Feb-2018 Completed Generating Revenue
To view Alpha Anomeric’s complete valuation and funding history, request access »

Alpha Anomeric Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A
To view Alpha Anomeric’s complete cap table history, request access »

Alpha Anomeric Patents

Alpha Anomeric Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2021382146-A1 Nucleic acid duplexes Pending 23-Nov-2020
AU-2021382146-A9 Nucleic acid duplexes Pending 23-Nov-2020
CA-3202708-A1 Nucleic acid duplexes Pending 23-Nov-2020
EP-4247949-A1 Nucleic acid duplexes Pending 23-Nov-2020
US-20240002853-A1 Nucleic acid duplexes Pending 23-Nov-2020 C12N15/113
To view Alpha Anomeric’s complete patent history, request access »

Alpha Anomeric Former Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds
Advent Life Sciences Venture Capital Minority
University of Bern University
To view Alpha Anomeric’s complete investors history, request access »

Alpha Anomeric FAQs

  • When was Alpha Anomeric founded?

    Alpha Anomeric was founded in 2018.

  • Where is Alpha Anomeric headquartered?

    Alpha Anomeric is headquartered in Paris, France.

  • What industry is Alpha Anomeric in?

    Alpha Anomeric’s primary industry is Drug Discovery.

  • Is Alpha Anomeric a private or public company?

    Alpha Anomeric is a Private company.

  • What is Alpha Anomeric’s current revenue?

    The current revenue for Alpha Anomeric is .

  • How much funding has Alpha Anomeric raised over time?

    Alpha Anomeric has raised $5.24M.

  • Who are Alpha Anomeric’s investors?

    Advent Life Sciences and University of Bern have invested in Alpha Anomeric.

  • When was Alpha Anomeric acquired?

    Alpha Anomeric was acquired on 29-Apr-2025.

  • Who acquired Alpha Anomeric?

    Alpha Anomeric was acquired by AlphaRose Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process